Adaptimmune has announced its first phase 2 data of their engineered T-cell receptor approach to solid tumours, from patients with rare soft-tissue sarcomas. The data come from 33 evaluated patients in a study that will eventually test the cell therapy in a total of 45 patients. Of those, 29 had synovial sarcoma, a cancer of the soft tissue that can be found in various parts of the body, and four had myxoid/round cell liposarcoma, a type of cancer that occurs in fat cells. All of the patients had tried at least three other lines of therapy. Source: Fierce Biotech 19/5/21